trial summary · NCT07802821
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
A Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Extensive-stage Small Cell Lung Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.
Source record: https://clinicaltrials.gov/study/NCT07802821
Facts
| registry id | NCT07802821 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Extensive-stage Small Cell Lung Cancer |
| sponsor | Qilu Pharmaceutical Co., Ltd. |
| sponsor class | INDUSTRY |
| enrollment | 556 |
| start date | 2026-10-27 |
| primary completion | 2029-03-15 |
| completion | 2030-06-15 |
| results posted | not reported |
Conditions
- Extensive-stage Small Cell Lung Cancer
Interventions
- QLC5508
- QL2107
- Tislelizumab
- Carboplatin
- Cisplatin
- Etoposide
Countries
- China
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.